Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

US pharma giant Eli Lilly joined hands with with Mumbai-based Cipla to market its insulin products in India.

The two companies announced a strategic partnership in India to enhance the reach of Lilly’s diabetes products – Humalog (Insulin Lispro) and Trulicity (Dulaglutide).

As part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the two Lilly diabetes products – Humalog and Trulicity to Cipla, subject to all regulatory approvals, Lilly said in a statement. Cipla stock was up marginally to Rs 987.6 apiece in morning trade on the BSE.

Lilly will continue to maintain